Shanghai Junshi Bioscience Co., Ltd.

This study tested whether adding the immunotherapy drug toripalimab to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 531 participants with metastatic or recurrent disease were enroll…

This study tested a new medicine called JS005, given as a shot under the skin, for adults with moderate to severe plaque psoriasis. The trial involved 747 people and compared JS005 to a placebo to see if it could clear skin symptoms. The main goals were to measure how many patien…

This study tested whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with advanced nasopharyngeal cancer that has come back or spread. About 289 adults were randomly assigned to receive either toripalimab plus chemo or a placebo plus chemo. Th…

This study tested a combination of two drugs, toripalimab and axitinib, against the standard drug sunitinib in 421 people with advanced kidney cancer that could not be removed by surgery. The goal was to see if the combo could slow cancer growth better than sunitinib alone. Parti…

This study tested a new drug called JS004, combined with another immunotherapy (toripalimab) and standard chemotherapy, in 119 people with advanced lung cancer. The main goals were to check safety and see if the combination helps shrink tumors. While not a cure, this approach aim…

This study tested whether a pre-filled syringe and an automatic injector deliver the same amount of JS005 into the body. 272 healthy adults received one injection and were followed for 85 days. The goal was to see if the two devices work equally well, not to treat any disease.